Nemolizumab
Galderma
['derm', 'galderma']
today, at the 2023 american academy of dermatology annual meeting, we presented the latest positive results from our phase iii trial in #prurigonodularis in the late-breaking session. find out more about our results and extensive presence at #aad here 
Advancing Dermatology for every skin story